Press Releases

Date Title and Summary View
Toggle Summary MediWound to Host a Key Opinion Leader Investor Day on EscharEx
In-Person KOL Breakfast Meeting to be held on Tuesday, July 12th in New York City YAVNE, Israel , July 05, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration,
View HTML
Toggle Summary MediWound Names Mr. Tzvi Palash as Chief Operating Officer
Brings Extensive Operational Experience from International Pharmaceutical Companies YAVNE, Israel , June 30, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration,
View HTML
Toggle Summary MediWound Announces CEO Transition
Ofer Gonen , current Board member and CEO of Clal Biotechnology Industries Ltd., appointed as New CEO – Effective June 30 Will replace current CEO Sharon Malka , who will join the Board of Directors YAVNE, Israel , May 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd.
View HTML
Toggle Summary MediWound Reports First Quarter 2022 Financial Results
Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds On track for NexoBrid BLA resubmission by mid-year Conference C all B egins T oday at 8:30 am ET   YAVNE, Israel , May 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd.
View HTML
Toggle Summary MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
Study Met Primary and Key Secondary Endpoints with Statistically Significant Results  Compared to Control Arms Significant Improvement Across Multiple Measures Over the Current Non-Surgical Standard-of Care No Deleterious Effect on Wound Closure and No Observed Safety Issues End of Phase 2 Meeting
View HTML
Toggle Summary MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022
YAVNE, Israel , May 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the first
View HTML
Toggle Summary MediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022
The poster, featuring the phase 2 pharmacology study promising results, was selected and featured during the Grand Rounds Session of the SAWC Wound Care Learning Network YAVNE, Israel , April 12, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company
View HTML
Toggle Summary MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022
Results Highlight the Safety and Efficacy in Hard-to-Heal Wounds SAWC to Take Place in Phoenix, Arizona on April 6-10, 2022 YAVNE, Israel , March 29, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic
View HTML
Toggle Summary MediWound Announces Exercise of Over-Allotment Option
YAVNE, Israel, March 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced that the underwriter of its
View HTML
Toggle Summary MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic Wounds
Primary Endpoint Met with Highly Statistically Significant Results Final Data Readout Expected in Second Quarter of 2022 YAVNE, Israel , March 21, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions
View HTML